Quick filters:
Moderna therapeutics Stock Photos and Images
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860333.htmlRMTB70AN–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/in-this-photo-illustration-a-medical-syringe-is-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-image378668454.htmlRM2D01RDA–In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background.
Brazil. 2nd Oct, 2020. In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-2nd-oct-2020-in-this-photo-illustration-a-medical-syringe-is-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-rafael-henriquesopa-imageszuma-wirealamy-live-news-image378647048.htmlRM2D00T4T–Brazil. 2nd Oct, 2020. In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News
Dr Melanie Ivarsson, Senior Vice President, Chief Development Officer, Moderna Therapeutics, United States of America with her OBE (Officer of the Order of the British Empire), presented to her by King Charles III, for services to Public Health during COVID-19, during an investiture ceremony at Windsor Castle, Berkshire. Picture date: Tuesday January 31, 2023. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/dr-melanie-ivarsson-senior-vice-president-chief-development-officer-moderna-therapeutics-united-states-of-america-with-her-obe-officer-of-the-order-of-the-british-empire-presented-to-her-by-king-charles-iii-for-services-to-public-health-during-covid-19-during-an-investiture-ceremony-at-windsor-castle-berkshire-picture-date-tuesday-january-31-2023-image512801683.htmlRM2MP83NR–Dr Melanie Ivarsson, Senior Vice President, Chief Development Officer, Moderna Therapeutics, United States of America with her OBE (Officer of the Order of the British Empire), presented to her by King Charles III, for services to Public Health during COVID-19, during an investiture ceremony at Windsor Castle, Berkshire. Picture date: Tuesday January 31, 2023.
In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/in-this-photo-illustration-various-medical-syringes-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-image388163658.htmlRM2DFEAKP–In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background
March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2). Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/march-17-2020-moderna-therapeutics-cambridge-massachusetts-usa-exterior-of-moderna-therapeutics-in-cambridge-massachusetts-usa-moderna-therapeutics-announced-that-it-has-dosed-the-first-patient-in-a-phase-i-study-evaluating-its-mrna-based-vaccine-candidate-mrna-1273-against-the-novel-coronavirus-sars-cov-2-image349020540.htmlRM2B7R778–March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2).
Moderna, 200 Technology Square, Cambridge, Massachusetts. storefront of a biotechnology and mRNA technology company. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/moderna-200-technology-square-cambridge-massachusetts-storefront-of-a-biotechnology-and-mrna-technology-company-image484601509.htmlRM2K4BE4N–Moderna, 200 Technology Square, Cambridge, Massachusetts. storefront of a biotechnology and mRNA technology company.
Person holding smartphone with logo of US pharmaceutical company Moderna Inc. on screen in front of website. Focus on phone display. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/person-holding-smartphone-with-logo-of-us-pharmaceutical-company-moderna-inc-on-screen-in-front-of-website-focus-on-phone-display-image560905451.htmlRF2RGFCHF–Person holding smartphone with logo of US pharmaceutical company Moderna Inc. on screen in front of website. Focus on phone display.
Medical syringe is seen with Moderna logo displayed on a screen in the background in this illustration photo taken in Poland on November 23, 2020. (Photo by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringe-is-seen-with-moderna-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-november-23-2020-photo-by-jakub-porzyckinurphoto-image489367619.htmlRM2KC4HAY–Medical syringe is seen with Moderna logo displayed on a screen in the background in this illustration photo taken in Poland on November 23, 2020. (Photo by Jakub Porzycki/NurPhoto)
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389530330.htmlRM2DHMHWE–Vaccine against Sars-CoV-2, Covid-19
Basel, Switzerland - April 20, 2024: Moderna is a biotechnology company focused on the discovery and development of mRNA-based drugs Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/basel-switzerland-april-20-2024-moderna-is-a-biotechnology-company-focused-on-the-discovery-and-development-of-mrna-based-drugs-image603957647.htmlRF2X2GJ3Y–Basel, Switzerland - April 20, 2024: Moderna is a biotechnology company focused on the discovery and development of mRNA-based drugs
Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/lisbon-portugal-november-22-2020-syringe-and-moderna-logo-on-the-background-coronavirus-covid-19-vaccine-concept-image386471402.htmlRF2DCN862–Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept
Moderna logo Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/moderna-logo-image385817454.htmlRM2DBKE2P–Moderna logo
Logo of the U.S. biopharmaceutical company Moderna with seat in Massachusetts - United States. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/logo-of-the-us-biopharmaceutical-company-moderna-with-seat-in-massachusetts-united-states-image382478338.htmlRM2D67B0J–Logo of the U.S. biopharmaceutical company Moderna with seat in Massachusetts - United States.
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860335.htmlRMTB70AR–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
Brazil. 2nd Oct, 2020. In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-2nd-oct-2020-in-this-photo-illustration-a-medical-syringe-is-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-rafael-henriquesopa-imageszuma-wirealamy-live-news-image392419676.htmlRM2DPC78C–Brazil. 2nd Oct, 2020. In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News
Dr Melanie Ivarsson, Senior Vice President, Chief Development Officer, Moderna Therapeutics, United States of America with her OBE (Officer of the Order of the British Empire), presented to her by King Charles III, for services to Public Health during COVID-19, during an investiture ceremony at Windsor Castle, Berkshire. Picture date: Tuesday January 31, 2023. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/dr-melanie-ivarsson-senior-vice-president-chief-development-officer-moderna-therapeutics-united-states-of-america-with-her-obe-officer-of-the-order-of-the-british-empire-presented-to-her-by-king-charles-iii-for-services-to-public-health-during-covid-19-during-an-investiture-ceremony-at-windsor-castle-berkshire-picture-date-tuesday-january-31-2023-image512801643.htmlRM2MP83MB–Dr Melanie Ivarsson, Senior Vice President, Chief Development Officer, Moderna Therapeutics, United States of America with her OBE (Officer of the Order of the British Empire), presented to her by King Charles III, for services to Public Health during COVID-19, during an investiture ceremony at Windsor Castle, Berkshire. Picture date: Tuesday January 31, 2023.
In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/in-this-photo-illustration-various-medical-syringes-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-image388163642.htmlRM2DFEAK6–In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background.
March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2). Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/march-17-2020-moderna-therapeutics-cambridge-massachusetts-usa-exterior-of-moderna-therapeutics-in-cambridge-massachusetts-usa-moderna-therapeutics-announced-that-it-has-dosed-the-first-patient-in-a-phase-i-study-evaluating-its-mrna-based-vaccine-candidate-mrna-1273-against-the-novel-coronavirus-sars-cov-2-image349020573.htmlRM2B7R78D–March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2).
Brazil. 13th Nov, 2020. In this photo illustration the medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background Credit: SOPA Images Limited/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-13th-nov-2020-in-this-photo-illustration-the-medical-syringe-is-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-sopa-images-limitedalamy-live-news-image385236105.htmlRM2DAN0G9–Brazil. 13th Nov, 2020. In this photo illustration the medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background Credit: SOPA Images Limited/Alamy Live News
Logo of Moderna, a biotechnology and mRNA technology company, at their 200 Technology Square building, Cambridge, Massachusetts Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/logo-of-moderna-a-biotechnology-and-mrna-technology-company-at-their-200-technology-square-building-cambridge-massachusetts-image484601508.htmlRM2K4BE4M–Logo of Moderna, a biotechnology and mRNA technology company, at their 200 Technology Square building, Cambridge, Massachusetts
Mobile phone with logo of American pharmaceutical company Moderna Inc. on screen in front of website. Focus on center-left of phone display. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/mobile-phone-with-logo-of-american-pharmaceutical-company-moderna-inc-on-screen-in-front-of-website-focus-on-center-left-of-phone-display-image560905504.htmlRF2RGFCKC–Mobile phone with logo of American pharmaceutical company Moderna Inc. on screen in front of website. Focus on center-left of phone display.
Medical syringes are seen with Moderna logo displayed on a screen in the background in this illustration photo taken in Poland on November 23, 2020. (Photo by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringes-are-seen-with-moderna-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-november-23-2020-photo-by-jakub-porzyckinurphoto-image489367622.htmlRM2KC4HB2–Medical syringes are seen with Moderna logo displayed on a screen in the background in this illustration photo taken in Poland on November 23, 2020. (Photo by Jakub Porzycki/NurPhoto)
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389530332.htmlRM2DHMHWG–Vaccine against Sars-CoV-2, Covid-19
Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on November 16, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringes-are-seen-with-moderna-company-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-november-16-2020-moderna-annoucnes-covid-19-vaccine-is-945-effective-photo-by-jakub-porzyckinurphoto-image489357720.htmlRM2KC44NC–Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on November 16, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto)
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389816231.htmlRM2DJ5JG7–Vaccine against Sars-CoV-2, Covid-19
Basel, Switzerland - April 20, 2024: Moderna is a biotechnology company focused on the discovery and development of mRNA-based drugs Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/basel-switzerland-april-20-2024-moderna-is-a-biotechnology-company-focused-on-the-discovery-and-development-of-mrna-based-drugs-image603957696.htmlRF2X2GJ5M–Basel, Switzerland - April 20, 2024: Moderna is a biotechnology company focused on the discovery and development of mRNA-based drugs
Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/lisbon-portugal-november-22-2020-syringe-and-moderna-logo-on-the-background-coronavirus-covid-19-vaccine-concept-image386471391.htmlRF2DCN85K–Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept
Moderna logo Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/moderna-logo-image385817190.htmlRM2DBKDNA–Moderna logo
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860334.htmlRMTB70AP–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
Brazil. 2nd Oct, 2020. In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-2nd-oct-2020-in-this-photo-illustration-a-medical-syringe-is-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-rafael-henriquesopa-imageszuma-wirealamy-live-news-image378674406.htmlRM2D0231X–Brazil. 2nd Oct, 2020. In this photo illustration a medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News
Brazil. 4th Dec, 2020. In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-4th-dec-2020-in-this-photo-illustration-various-medical-syringes-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-rafael-henriquesopa-imageszuma-wirealamy-live-news-image388164453.htmlRM2DFEBM5–Brazil. 4th Dec, 2020. In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News
March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2). Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/march-17-2020-moderna-therapeutics-cambridge-massachusetts-usa-exterior-of-moderna-therapeutics-in-cambridge-massachusetts-usa-moderna-therapeutics-announced-that-it-has-dosed-the-first-patient-in-a-phase-i-study-evaluating-its-mrna-based-vaccine-candidate-mrna-1273-against-the-novel-coronavirus-sars-cov-2-image349020539.htmlRM2B7R777–March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2).
Brazil. 13th Nov, 2020. In this photo illustration the medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background Credit: SOPA Images Limited/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-13th-nov-2020-in-this-photo-illustration-the-medical-syringe-is-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-sopa-images-limitedalamy-live-news-image385236163.htmlRM2DAN0JB–Brazil. 13th Nov, 2020. In this photo illustration the medical syringe is seen with Moderna Therapeutics company logo displayed on a screen in the background Credit: SOPA Images Limited/Alamy Live News
Person holding cellphone with webpage of US pharmaceutical company Moderna Inc. on screen in front of logo. Focus on center of phone display. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/person-holding-cellphone-with-webpage-of-us-pharmaceutical-company-moderna-inc-on-screen-in-front-of-logo-focus-on-center-of-phone-display-image560905526.htmlRF2RGFCM6–Person holding cellphone with webpage of US pharmaceutical company Moderna Inc. on screen in front of logo. Focus on center of phone display.
Medical syringes are seen with ' COVID-19 ' sign displayed on a screen in the background in this illustration photo taken in Poland on November 15, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringes-are-seen-with-covid-19-sign-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-november-15-2020-moderna-annoucnes-covid-19-vaccine-is-945-effective-photo-by-jakub-porzyckinurphoto-image489357718.htmlRM2KC44NA–Medical syringes are seen with ' COVID-19 ' sign displayed on a screen in the background in this illustration photo taken in Poland on November 15, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto)
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389530338.htmlRM2DHMHWP–Vaccine against Sars-CoV-2, Covid-19
Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/lisbon-portugal-november-22-2020-syringe-and-moderna-logo-on-the-background-coronavirus-covid-19-vaccine-concept-image386471150.htmlRF2DCN7W2–Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept
Moderna logo icon Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/moderna-logo-icon-image385817428.htmlRM2DBKE1T–Moderna logo icon
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860328.htmlRMTB70AG–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
Brazil. 4th Dec, 2020. In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-4th-dec-2020-in-this-photo-illustration-various-medical-syringes-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-rafael-henriquesopa-imageszuma-wirealamy-live-news-image388164075.htmlRM2DFEB6K–Brazil. 4th Dec, 2020. In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News
March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2). Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/march-17-2020-moderna-therapeutics-cambridge-massachusetts-usa-exterior-of-moderna-therapeutics-in-cambridge-massachusetts-usa-moderna-therapeutics-announced-that-it-has-dosed-the-first-patient-in-a-phase-i-study-evaluating-its-mrna-based-vaccine-candidate-mrna-1273-against-the-novel-coronavirus-sars-cov-2-image349020541.htmlRM2B7R779–March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2).
Person holding cellphone with logo of US pharmaceutical company Moderna Inc. on screen in front of business webpage. Focus on phone display. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/person-holding-cellphone-with-logo-of-us-pharmaceutical-company-moderna-inc-on-screen-in-front-of-business-webpage-focus-on-phone-display-image560905487.htmlRF2RGFCJR–Person holding cellphone with logo of US pharmaceutical company Moderna Inc. on screen in front of business webpage. Focus on phone display.
Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on November 16, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringes-are-seen-with-moderna-company-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-november-16-2020-moderna-annoucnes-covid-19-vaccine-is-945-effective-photo-by-jakub-porzyckinurphoto-image489357717.htmlRM2KC44N9–Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on November 16, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto)
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389530343.htmlRM2DHMHWY–Vaccine against Sars-CoV-2, Covid-19
Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/lisbon-portugal-november-22-2020-syringe-and-moderna-logo-on-the-background-coronavirus-covid-19-vaccine-concept-image386471197.htmlRF2DCN7XN–Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860338.htmlRMTB70AX–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
Brazil. 4th Dec, 2020. In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/brazil-4th-dec-2020-in-this-photo-illustration-various-medical-syringes-seen-with-moderna-therapeutics-company-logo-displayed-on-a-screen-in-the-background-credit-rafael-henriquesopa-imageszuma-wirealamy-live-news-image392419295.htmlRM2DPC6PR–Brazil. 4th Dec, 2020. In this photo illustration various medical syringes seen with Moderna Therapeutics company logo displayed on a screen in the background. Credit: Rafael Henrique/SOPA Images/ZUMA Wire/Alamy Live News
March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2). Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/march-17-2020-moderna-therapeutics-cambridge-massachusetts-usa-exterior-of-moderna-therapeutics-in-cambridge-massachusetts-usa-moderna-therapeutics-announced-that-it-has-dosed-the-first-patient-in-a-phase-i-study-evaluating-its-mrna-based-vaccine-candidate-mrna-1273-against-the-novel-coronavirus-sars-cov-2-image349020542.htmlRM2B7R77A–March 17, 2020, Moderna Therapeutics, Cambridge, Massachusetts, USA: Exterior of Moderna Therapeutics in Cambridge, Massachusetts USA. Moderna Therapeutics announced that it has dosed the first patient in a phase I study, evaluating its mRNA-based vaccine candidate, mRNA-1273, against the novel coronavirus (SARS-CoV-2).
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198839.htmlRM2C9B9T7–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Smartphone with website of US pharmaceutical company Moderna Inc. on screen in front of business logo. Focus on top-left of phone display. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/smartphone-with-website-of-us-pharmaceutical-company-moderna-inc-on-screen-in-front-of-business-logo-focus-on-top-left-of-phone-display-image560905514.htmlRF2RGFCKP–Smartphone with website of US pharmaceutical company Moderna Inc. on screen in front of business logo. Focus on top-left of phone display.
Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on November 15, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringes-are-seen-with-moderna-company-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-november-15-2020-moderna-annoucnes-covid-19-vaccine-is-945-effective-photo-by-jakub-porzyckinurphoto-image489357716.htmlRM2KC44N8–Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on November 15, 2020. Moderna annoucnes COVID-19 vaccine is 94.5 % effective. (Photo by Jakub Porzycki/NurPhoto)
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389816236.htmlRM2DJ5JGC–Vaccine against Sars-CoV-2, Covid-19
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395978.htmlRM2KC5WFP–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/lisbon-portugal-november-22-2020-syringe-and-moderna-logo-on-the-background-coronavirus-covid-19-vaccine-concept-image386471393.htmlRF2DCN85N–Lisbon, Portugal - November 22, 2020: Syringe and Moderna logo on the background. Coronavirus, Covid-19 vaccine concept
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860329.htmlRMTB70AH–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198864.htmlRM2C9B9W4–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Person holding mobile phone with logo of American pharmaceutical company Moderna Inc. on screen in front of web page. Focus on phone display. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/person-holding-mobile-phone-with-logo-of-american-pharmaceutical-company-moderna-inc-on-screen-in-front-of-web-page-focus-on-phone-display-image560905437.htmlRF2RGFCH1–Person holding mobile phone with logo of American pharmaceutical company Moderna Inc. on screen in front of web page. Focus on phone display.
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389816226.htmlRM2DJ5JG2–Vaccine against Sars-CoV-2, Covid-19
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395981.htmlRM2KC5WFW–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860322.htmlRMTB70AA–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198831.htmlRM2C9B9RY–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Person holding mobile phone with web page of US pharmaceutical company Moderna Inc. on screen in front of logo. Focus on center of phone display. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/person-holding-mobile-phone-with-web-page-of-us-pharmaceutical-company-moderna-inc-on-screen-in-front-of-logo-focus-on-center-of-phone-display-image560905535.htmlRF2RGFCMF–Person holding mobile phone with web page of US pharmaceutical company Moderna Inc. on screen in front of logo. Focus on center of phone display.
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389816228.htmlRM2DJ5JG4–Vaccine against Sars-CoV-2, Covid-19
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395974.htmlRM2KC5WFJ–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019. Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/a-logo-sign-outside-of-the-headquarters-of-moderna-therapeutics-in-cambridge-massachusetts-on-april-29-2019-image247860327.htmlRMTB70AF–A logo sign outside of the headquarters of Moderna Therapeutics in Cambridge, Massachusetts on April 29, 2019.
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198862.htmlRM2C9B9W2–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389816330.htmlRM2DJ5JKP–Vaccine against Sars-CoV-2, Covid-19
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395982.htmlRM2KC5WFX–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198855.htmlRM2C9B9TR–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389816321.htmlRM2DJ5JKD–Vaccine against Sars-CoV-2, Covid-19
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395973.htmlRM2KC5WFH–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389130183.htmlRM2DH2BEF–Vaccine against Sars-CoV-2, Covid-19
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image389816322.htmlRM2DJ5JKE–Vaccine against Sars-CoV-2, Covid-19
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198832.htmlRM2C9B9T0–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395979.htmlRM2KC5WFR–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image387351965.htmlRM2DE5BAN–Vaccine against Sars-CoV-2, Covid-19
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198828.htmlRM2C9B9RT–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395972.htmlRM2KC5WFG–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image387352025.htmlRF2DE5BCW–Vaccine against Sars-CoV-2, Covid-19
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198837.htmlRM2C9B9T5–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395977.htmlRM2KC5WFN–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image387351961.htmlRF2DE5BAH–Vaccine against Sars-CoV-2, Covid-19
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198854.htmlRM2C9B9TP–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395975.htmlRM2KC5WFK–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image387351963.htmlRM2DE5BAK–Vaccine against Sars-CoV-2, Covid-19
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198841.htmlRM2C9B9T9–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395980.htmlRM2KC5WFT–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/photo-illustration-of-a-medical-syringe-with-a-needle-seen-in-front-of-the-moderna-pharmaceutical-corporation-logo-moderna-expects-the-american-decision-an-approval-for-emergency-use-the-vaccine-candidate-mrna-1273-on-december-17-2020-from-the-fda-and-european-approval-for-covid-19-vaccine-in-january-of-2021-moderna-is-an-american-biotechnology-company-based-in-cambridge-massachusetts-developing-vaccine-technologies-based-on-messenger-rna-mrna-the-coronavirus-pandemic-one-of-the-biggest-healthcare-crisis-in-the-world-will-result-in-the-largest-vaccination-program-in-human-history-amste-image489395970.htmlRM2KC5WFE–Photo illustration of a medical syringe with a needle seen in front of the Moderna pharmaceutical corporation logo. Moderna expects the American decision, an approval for emergency use, the vaccine candidate mRNA-1273 on December 17 2020 from the FDA and European approval for COVID-19 vaccine in January of 2021. Moderna is an American biotechnology company based in Cambridge, Massachusetts developing vaccine technologies based on messenger RNA mRNA. The Coronavirus pandemic, one of the biggest healthcare crisis in the world will result in the largest vaccination program in human history. Amste
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image387352020.htmlRF2DE5BCM–Vaccine against Sars-CoV-2, Covid-19
Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on October 12, 2020. (Photo illustration by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringes-are-seen-with-moderna-company-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-october-12-2020-photo-illustration-by-jakub-porzyckinurphoto-image489304282.htmlRM2KC1MGX–Medical syringes are seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on October 12, 2020. (Photo illustration by Jakub Porzycki/NurPhoto)
Coronavirus model and medical syringe are seen in this illustration photo taken in Poland on June 9, 2020. American biotech company Moderna has announced on June 11 that will start final stage of covid-19 vaccine trial in July. (Photo Illustration by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/coronavirus-model-and-medical-syringe-are-seen-in-this-illustration-photo-taken-in-poland-on-june-9-2020-american-biotech-company-moderna-has-announced-on-june-11-that-will-start-final-stage-of-covid-19-vaccine-trial-in-july-photo-illustration-by-jakub-porzyckinurphoto-image489159510.htmlRM2KBR3XE–Coronavirus model and medical syringe are seen in this illustration photo taken in Poland on June 9, 2020. American biotech company Moderna has announced on June 11 that will start final stage of covid-19 vaccine trial in July. (Photo Illustration by Jakub Porzycki/NurPhoto)
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198833.htmlRM2C9B9T1–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image387351971.htmlRM2DE5BAY–Vaccine against Sars-CoV-2, Covid-19
Medical syringe is seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on June 12, 2020. American biotech company Moderna has announced on June 11 that will start final stage of covid-19 vaccine trial in July. (Photo Illustration by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringe-is-seen-with-moderna-company-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-june-12-2020-american-biotech-company-moderna-has-announced-on-june-11-that-will-start-final-stage-of-covid-19-vaccine-trial-in-july-photo-illustration-by-jakub-porzyckinurphoto-image489159502.htmlRM2KBR3X6–Medical syringe is seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on June 12, 2020. American biotech company Moderna has announced on June 11 that will start final stage of covid-19 vaccine trial in July. (Photo Illustration by Jakub Porzycki/NurPhoto)
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198843.htmlRM2C9B9TB–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
Vaccine against Sars-CoV-2, Covid-19 Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/vaccine-against-sars-cov-2-covid-19-image387351974.htmlRM2DE5BB2–Vaccine against Sars-CoV-2, Covid-19
Medical syringe is seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on June 12, 2020. American biotech company Moderna has announced on June 11 that will start final stage of covid-19 vaccine trial in July. (Photo Illustration by Jakub Porzycki/NurPhoto) Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/medical-syringe-is-seen-with-moderna-company-logo-displayed-on-a-screen-in-the-background-in-this-illustration-photo-taken-in-poland-on-june-12-2020-american-biotech-company-moderna-has-announced-on-june-11-that-will-start-final-stage-of-covid-19-vaccine-trial-in-july-photo-illustration-by-jakub-porzyckinurphoto-image489159514.htmlRM2KBR3XJ–Medical syringe is seen with Moderna company logo displayed on a screen in the background in this illustration photo taken in Poland on June 12, 2020. American biotech company Moderna has announced on June 11 that will start final stage of covid-19 vaccine trial in July. (Photo Illustration by Jakub Porzycki/NurPhoto)
Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News Stock Photohttps://www.alamy.com/image-license-details/?v=1https://www.alamy.com/cambridge-massachusetts-usa-29th-mar-2016-noubar-afeyan-noubar-afeyan-founder-and-ceo-of-flagship-pioneering-a-cambridge-mass-biotech-incubator-that-has-many-biotech-companies-in-its-portfolio-including-moderna-therapeutics-currently-engaged-in-human-trials-of-a-vaccine-to-cure-the-covid-19-corona-virus-afeyan-was-a-keynote-speaker-at-the-sloan-school-at-mit-for-the-luys-foundation-of-armenia-credit-kenneth-martinzuma-wirealamy-live-news-image367198827.htmlRM2C9B9RR–Cambridge, Massachusetts, USA. 29th Mar, 2016. NOUBAR AFEYAN - Noubar Afeyan, founder and CEO of Flagship Pioneering, a Cambridge, Mass., biotech incubator that has many biotech companies in its portfolio including Moderna Therapeutics currently engaged in human trials of a vaccine to cure the Covid-19 Corona Virus. Afeyan was a keynote speaker at the Sloan School at MIT for the Luys Foundation of Armenia. Credit: Kenneth Martin/ZUMA Wire/Alamy Live News
